Supriya Lifescience Limited (NSE:SUPRIYA)

Market Cap	49.96B -15.5%
Revenue (ttm)	7.35B +9.7%
Net Income	1.85B +6.2%
EPS	23.04 +6.4%
Shares Out	80.48M
PE Ratio	26.94
Forward PE	21.12
Dividend	1.00 (0.16%)
Ex-Dividend Date	Sep 4, 2025

Volume	403,654
Average Volume	151,657
Open	621.75
Previous Close	620.75
Day's Range	620.00 - 660.00
52-Week Range	545.50 - 832.40
Beta	0.28
RSI	58.18
Earnings Date	May 26, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 515
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUPRIYA

Financial Performance

In fiscal year 2025, Supriya Lifescience's revenue was 6.96 billion, an increase of 22.12% compared to the previous year's 5.70 billion. Earnings were 1.88 billion, an increase of 57.80%.